Division of HIV, Infectious Diseases, and Global Medicine, University of California, San Francisco, USA.
The Wistar Institute, Philadelphia, PA, USA.
Semin Immunol. 2024 Mar;72:101873. doi: 10.1016/j.smim.2024.101873. Epub 2024 Mar 8.
Since the onset of the COVID-19 pandemic, significant progress has been made in developing effective preventive and therapeutic strategies against severe acute SARS-CoV-2 infection. However, the management of Long COVID (LC), an infection-associated chronic condition that has been estimated to affect 5-20% of individuals following SARS-CoV-2 infection, remains challenging due to our limited understanding of its mechanisms. Although LC is a heterogeneous disease that is likely to have several subtypes, immune system disturbances appear common across many cases. The extent to which these immune perturbations contribute to LC symptoms, however, is not entirely clear. Recent advancements in multi-omics technologies, capable of detailed, cell-level analysis, have provided valuable insights into the immune perturbations associated with LC. Although these studies are largely descriptive in nature, they are the crucial first step towards a deeper understanding of the condition and the immune system's role in its development, progression, and resolution. In this review, we summarize the current understanding of immune perturbations in LC, covering both innate and adaptive immune responses, and the cytokines and analytes involved. We explore whether these findings support or challenge the primary hypotheses about LC's underlying mechanisms. We also discuss the crosstalk between various immune system components and how it can be disrupted in LC. Finally, we emphasize the need for more tissue- and subtype-focused analyses of LC, and for enhanced collaborative efforts to analyze common specimens from large cohorts, including those undergoing therapeutic interventions. These collective efforts are vital to unravel the fundaments of this new disease, and could also shed light on the prevention and treatment of the larger family of chronic illnesses linked to other microbial infections.
自 COVID-19 大流行以来,在开发针对严重急性 SARS-CoV-2 感染的有效预防和治疗策略方面取得了重大进展。然而,由于我们对其机制的了解有限,管理与 SARS-CoV-2 感染相关的慢性疾病——长新冠(LC)仍然具有挑战性。尽管 LC 是一种异质性疾病,可能有几种亚型,但许多病例中都存在免疫系统紊乱。然而,这些免疫扰动在多大程度上导致了 LC 症状尚不完全清楚。最近多组学技术的进步,能够进行详细的细胞水平分析,为 LC 相关的免疫扰动提供了有价值的见解。尽管这些研究在很大程度上是描述性的,但它们是深入了解该疾病以及免疫系统在其发展、进展和解决中的作用的关键第一步。在这篇综述中,我们总结了目前对 LC 中免疫扰动的理解,涵盖了先天和适应性免疫反应以及涉及的细胞因子和分析物。我们探讨了这些发现是否支持或挑战 LC 潜在机制的主要假设。我们还讨论了各种免疫系统成分之间的串扰以及它如何在 LC 中被破坏。最后,我们强调了需要对 LC 进行更多的组织和亚型聚焦分析,并需要加强协作努力,分析来自大样本队列的常见标本,包括接受治疗干预的队列。这些共同的努力对于揭示这种新疾病的基础至关重要,也可能为预防和治疗与其他微生物感染相关的更大的慢性疾病家族提供线索。